The First HIV Integrase Inhibitor: Raltegravir
Raltegravir is the first integraseinhibitor to be approved by the US Food and Drug Administration for use in antiretroviral treatment–experienced adult patients with viral resistance. Raltegravir blocks HIV replication by inhibitingessential strand-transfer activities of integrase. Raltegravir is rapidly absorbed, with a median Tmax of~4 hours in the fasting state. No dose adjustment is recommended in patients with moderate renal or hepaticinsufficiency, and raltegravir may be taken withoutregard to meals. Subscribe to Drugs Information Center by Email